These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16737009)

  • 21. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost of coronary heart disease in New Zealand.
    Scott WG; White HD; Scott HM
    N Z Med J; 1993 Aug; 106(962):347-9. PubMed ID: 8255558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A note in support of reversal treatment for coronary artery disease.
    Lane DM
    J Okla State Med Assoc; 1995 Apr; 88(4):165-7. PubMed ID: 7782964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of accepted measures for intervention in coronary heart disease.
    Kuntz KM; Lee TH
    Coron Artery Dis; 1995 Jun; 6(6):472-8. PubMed ID: 7551268
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of neural network models for the prediction of the cost of care for acute coronary syndrome patients.
    Ismael MB; Eisenstein EL; Hammond WE
    Proc AMIA Symp; 1998; ():533-7. PubMed ID: 9929276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
    Chino M; Sasaki T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
    [No Abstract]   [Full Text] [Related]  

  • 27. DTB position on drug costs.
    Drug Ther Bull; 1993 May; 31(11):44. PubMed ID: 8344137
    [No Abstract]   [Full Text] [Related]  

  • 28. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomics and the formulary decision-making process.
    Bakst A
    Hosp Formul; 1995 Jan; 30(1):42-50. PubMed ID: 10172201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradigm shifts in cardiovascular medicine.
    Holmes DR; Firth BG; Wood DL
    J Am Coll Cardiol; 2004 Feb; 43(4):507-12. PubMed ID: 14975455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease.
    Hlatky MA; Boothroyd DB; Melsop KA; Brooks MM; Mark DB; Pitt B; Reeder GS; Rogers WJ; Ryan TJ; Whitlow PL; Wiens RD
    Circulation; 2004 Oct; 110(14):1960-6. PubMed ID: 15451795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heart catheter in stable coronary heart disease. Drugs are equally effective].
    Einecke D
    MMW Fortschr Med; 2007 Apr; 149(15):10, 12. PubMed ID: 17668771
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 35. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A look at cost-effectiveness.
    Gibaldi M; Sullivan SD
    Pharmacotherapy; 1994; 14(4):399-414. PubMed ID: 7937277
    [No Abstract]   [Full Text] [Related]  

  • 37. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators.
    Hlatky MA; Rogers WJ; Johnstone I; Boothroyd D; Brooks MM; Pitt B; Reeder G; Ryan T; Smith H; Whitlow P; Wiens R; Mark DB
    N Engl J Med; 1997 Jan; 336(2):92-9. PubMed ID: 8988886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and economic aspects of chronic coronary restenosis: potential advantage of intracoronary brachytherapy].
    Schiele TM; Siebert U; Cohen D; Klauss V
    Dtsch Med Wochenschr; 2001 Apr; 126(15):440-4. PubMed ID: 11347008
    [No Abstract]   [Full Text] [Related]  

  • 39. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system.
    Weintraub WS; Warner CD; Mauldin PD; Becker ER; Gomes D; Cook J; Kosinski A; Boccuzzi S
    Am J Manag Care; 1997 May; 3(5):743-9. PubMed ID: 10169536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity and long-term clinical and economic outcomes in coronary artery disease patients.
    Eisenstein EL; Shaw LK; Nelson CL; Anstrom KJ; Hakim Z; Mark DB
    Obes Res; 2002 Feb; 10(2):83-91. PubMed ID: 11836453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.